Literature DB >> 30535032

The Role of Standard and Advanced Imaging for the Management of Brain Malignancies From a Radiation Oncology Standpoint.

Robert H Press1, Jim Zhong1, Saumya S Gurbani2,3, Brent D Weinberg2, Bree R Eaton1, Hyunsuk Shim1,2,3, Hui-Kuo G Shu1.   

Abstract

Radiation therapy (RT) plays a critical role in the overall management of many central nervous system (CNS) tumors. Advances in RT treatment planning, with techniques such as intensity modulated radiation therapy, volumetric modulated arc therapy, and stereotactic radiosurgery, now allow the delivery of highly conformal dose with great precision. These techniques rely on high-resolution 3-dimensional anatomical imaging modalities such as computed tomography or magnetic resonance imaging (MRI) scans to accurately and reliably define CNS targets and normal tissue avoidance structures. The integration of cross-sectional imaging into radiation oncology has directly translated into improvements in the therapeutic window of RT, and the union between radiation oncology and imaging is only expected to grow stronger. In addition, advanced imaging modalities including diffusion, perfusion, and spectroscopic MRIs as well as positron emission tomography (PET) scans with novel tracers are being utilized to provide additional insight into tumor biology and behavior beyond anatomy. Together, these standard and advanced imaging modalities hold significant potential to improve future RT delivery and response assessment. In this review, we will discuss the current utilization of standard/advanced imaging for CNS tumors from a radiation oncology perspective as well as the implications of novel MRI and PET modalities currently under investigation.
Copyright © 2018 by the Congress of Neurological Surgeons.

Entities:  

Keywords:  Biological imaging; Brain metastases; Glioma; MRI; PET

Mesh:

Year:  2019        PMID: 30535032      PMCID: PMC6904726          DOI: 10.1093/neuros/nyy461

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  156 in total

Review 1.  Issues of spectral quality in clinical 1H-magnetic resonance spectroscopy and a gallery of artifacts.

Authors:  Roland Kreis
Journal:  NMR Biomed       Date:  2004-10       Impact factor: 4.044

2.  Radiation-induced apoptosis of endothelial cells in the murine central nervous system: protection by fibroblast growth factor and sphingomyelinase deficiency.

Authors:  L A Peña; Z Fuks; R N Kolesnick
Journal:  Cancer Res       Date:  2000-01-15       Impact factor: 12.701

Review 3.  Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas.

Authors:  Dieta Brandsma; Lukas Stalpers; Walter Taal; Peter Sminia; Martin J van den Bent
Journal:  Lancet Oncol       Date:  2008-05       Impact factor: 41.316

4.  Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial.

Authors:  Kathleen M Schmainda; Zheng Zhang; Melissa Prah; Bradley S Snyder; Mark R Gilbert; A Gregory Sorensen; Daniel P Barboriak; Jerrold L Boxerman
Journal:  Neuro Oncol       Date:  2015-02-02       Impact factor: 12.300

Review 5.  Clinical applications of PET in brain tumors.

Authors:  Wei Chen
Journal:  J Nucl Med       Date:  2007-08-17       Impact factor: 10.057

6.  The late effects of radiation on the blood brain barrier.

Authors:  M P Remler; W H Marcussen; J Tiller-Borsich
Journal:  Int J Radiat Oncol Biol Phys       Date:  1986-11       Impact factor: 7.038

7.  (18)F-FDOPA PET for differentiating recurrent or progressive brain metastatic tumors from late or delayed radiation injury after radiation treatment.

Authors:  Karlo J Lizarraga; Martin Allen-Auerbach; Johannes Czernin; Antonio A F DeSalles; William H Yong; Michael E Phelps; Wei Chen
Journal:  J Nucl Med       Date:  2013-10-28       Impact factor: 10.057

8.  Early posttreatment assessment of MRI perfusion biomarkers can predict long-term response of lung cancer brain metastases to stereotactic radiosurgery.

Authors:  Neil K Taunk; Jung Hun Oh; Amita Shukla-Dave; Kathryn Beal; Behroze Vachha; Andrei Holodny; Vaios Hatzoglou
Journal:  Neuro Oncol       Date:  2018-03-27       Impact factor: 12.300

9.  Amino-acid PET versus MRI guided re-irradiation in patients with recurrent glioblastoma multiforme (GLIAA) - protocol of a randomized phase II trial (NOA 10/ARO 2013-1).

Authors:  Oliver Oehlke; Michael Mix; Erika Graf; Tanja Schimek-Jasch; Ursula Nestle; Irina Götz; Sabine Schneider-Fuchs; Astrid Weyerbrock; Irina Mader; Brigitta G Baumert; Susan C Short; Philipp T Meyer; Wolfgang A Weber; Anca-Ligia Grosu
Journal:  BMC Cancer       Date:  2016-10-05       Impact factor: 4.430

10.  Adaptive hypofractionated gamma knife radiosurgery for a large brainstem metastasis.

Authors:  Georges Sinclair; Jiri Bartek; Heather Martin; Pierre Barsoum; Ernest Dodoo
Journal:  Surg Neurol Int       Date:  2016-02-10
View more
  2 in total

1.  Impacts of genotypic variants on survival following reoperation for recurrent glioblastoma.

Authors:  Antonio Dono; Ping Zhu; Emma Holmes; Takeshi Takayasu; Jay-Jiguang Zhu; Angel I Blanco; Sigmund Hsu; Meenakshi B Bhattacharjee; Leomar Y Ballester; Dong H Kim; Yoshua Esquenazi; Nitin Tandon
Journal:  J Neurooncol       Date:  2022-01-08       Impact factor: 4.506

2.  Does the dural resection bed need to be irradiated? Patterns of recurrence and implications for postoperative radiotherapy for temporal lobe gliomas.

Authors:  Achiraya Teyateeti; Connie S Geno; Scott S Stafford; Anita Mahajan; Elizabeth S Yan; Kenneth W Merrell; Nadia N Laack; Ian F Parney; Paul D Brown; Krishan R Jethwa
Journal:  Neurooncol Pract       Date:  2020-11-04
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.